Avicanna Completes Successful Private Placement
In a significant move, Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) has successfully completed a non-brokered private placement of 4,000,000 units, raising an impressive $1,000,000. Each unit, priced at $0.25, comprises one common share and half a common share purchase warrant. This means investors are now incentivized to participate further as each whole warrant allows the purchase of one additional share at $0.30 up until July 16, 2028.
Intended Use of Proceeds
The capital raised will be critical for Avicanna as it heads towards its objectives. The funds are earmarked for general working capital, which includes general and administrative expenses, as well as for enhancing production and manufacturing capabilities. Importantly, a portion of the funding will support ongoing research and clinical development initiatives.
Company Growth and Product Development
Avicanna is a pioneering biopharmaceutical company that focuses on creating and commercializing cannabinoid-based products aimed at the medical and pharmaceutical sectors. With a portfolio of over thirty proprietary products, the company's commitment to advancing cannabinoid science is evident through its structured research and development framework.
RHO Phyto™ Medical Cannabis Formulary
The RHO Phyto™ formulary offers an extensive range of innovative medical cannabis products, ranging from oral to topical solutions. These products are designed with varying cannabinoid ratios and are complemented by educational initiatives for both patients and healthcare professionals. Currently, RHO Phyto is a recognized brand across Canada and is looking to expand into international markets, fulfilling a growing demand.
MyMedi.ca: A Supportive Platform for Patients
MyMedi.ca was created to address the medical cannabis needs of patients effectively. This platform provides comprehensive services operated by Northern Green Canada Inc., which includes a bilingual pharmacist-led support system. By offering educational resources and specialty services, MyMedi.ca enhances the medical journey for cannabis patients, especially veterans, making it a valuable resource in the healthcare landscape.
Innovative Pharmaceutical Pipeline
Leveraging its scientific expertise, Avicanna has developed a strong pipeline of proprietary cannabinoid-based formulations targeting unmet medical needs in various fields, including dermatology and chronic pain. This innovative approach underscores the company’s commitment to creating effective therapeutic options.
Active Pharmaceutical Ingredients from Santa Marta Golden Hemp
Avicanna's subsidiary, Santa Marta Golden Hemp SAS (SMGH), plays a crucial role in providing high-quality active pharmaceutical ingredients. This aspect of the business not only strengthens Avicanna’s supply chain but also supports its diverse range of consumer, medical, and pharmaceutical products globally. The commitment to quality ensures that Avicanna maintains a competitive edge in the market.
Conclusion
By closing this private placement, Avicanna stands poised for growth and continued leadership in the cannabinoid space. The funding will enable the company to further its innovative product development, support patient needs, and expand its market reach. With a focus on advancing cannabinoid-based therapies and comprehensive patient support mechanisms, Avicanna is set to play a significant role in the future of medical cannabinoid utilization.
Frequently Asked Questions
What is Avicanna's primary focus?
Avicanna is focused on developing, manufacturing, and commercializing plant-derived cannabinoid products for the medical and pharmaceutical markets.
How much did Avicanna raise in its recent placement?
The company raised $1,000,000 through a private placement of 4,000,000 units.
What can investors do with the warrants they received?
Investors holding warrants can purchase one common share of Avicanna at an exercise price of $0.30 until July 16, 2028.
What are the intended uses for the funds raised?
The proceeds will be utilized for general working capital, production, manufacturing expenses, and ongoing research and clinical development initiatives.
How does Avicanna support medical cannabis patients?
Through platforms like MyMedi.ca, Avicanna provides essential support and educational resources tailored to medical cannabis patients, enhancing their experience and care.
